The Products investment objective is to replicate, before fees and expenses, the MVIS Global Bionic Healthcare ESG Index (the Index). The Product, using a passive or indexing investment approach, attempts to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index. The Investment Manager will regularly monitor the Product's tracking accuracy. The annualised tracking error envisaged is not anticipated to exceed 0.2% under normal market conditions.